QURE UNIQURE NV

uniQure to Participate in Multiple Upcoming Industry Conferences in October

uniQure to Participate in Multiple Upcoming Industry Conferences in October

LEXINGTON, Mass. and AMSTERDAM, Sept. 30, 2020 (GLOBE NEWSWIRE) -- (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that Matt Kapusta, chief executive officer at uniQure, Maria Cantor, chief communications officer, and Chiara Russo, associate director of investor relations and communications, will participate in the following upcoming conferences in October:

  • SVB Leerink CybeRx Series: Rare & Genetics, October 1, 2020



    • Members of uniQure’s management team will participate in virtual one-on-one investor meetings in the afternoon on Thursday, October 1, 2020.



  • Jefferies Virtual Gene Therapy/Editing Summit, October 1 – 2, 2020



    • A fireside chat with research analyst Suji Jeong, Ph.D. will take place on Friday, October 2, 2020 from 9:00 – 9:25 a.m. ET. The live webcast of the chat can be accessed through the link displayed in the of the uniQure website. The webcast replay will be available for at least 72 hours following the live event.



    • Members of uniQure’s management team will participate in virtual one-on-one investor meetings throughout the morning on Friday, October 2, 2020.



  • Chardan Virtual 4th Annual Genetic Medicines Conference, October 5 – 6, 2020



    • A fireside chat with research analyst Gbola Amusa will take place on Tuesday, October 6, 2020 from 1:00 – 1:25 p.m. ET. The live webcast of the chat can be accessed through the link displayed in the of the uniQure website. The webcast replay will be available for at least 72 hours following the live event.



    • Members of uniQure’s management team will participate in virtual one-on-one investor meetings throughout the afternoon on Tuesday, October 6, 2020.

About uniQure

uniQure is delivering on the promise of gene therapy – single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a of proprietary gene therapies to treat patients with hemophilia B, Huntington's disease, Fabry disease, spinocerebellar ataxia Type 3 and other diseases. 

uniQure Contacts:
   
FOR INVESTORS: FOR MEDIA:
   
Maria E. CantorChiara RussoTom Malone
Direct: 339-970-7536Direct: 617-306-9137Direct: 339-970-7558
  



EN
30/09/2020

Underlying

QUREUNIQURE NV

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on UNIQURE NV

 PRESS RELEASE
Free
QURE UNIQURE NV

uniQure Announces 2025 Financial Results and Provides Recent Company U...

uniQure Announces 2025 Financial Results and Provides Recent Company Updates ~ Held Type A meeting with FDA to discuss AMT-130 for Huntington’s disease; Company evaluating Phase III development considerations and plans to request follow-up Type B meeting in the second quarter of 2026 ~ ~ Completed enrollment of the first cohort in the Phase I/IIa study of AMT-260 in refractory mesial temporal lobe epilepsy, with additional clinical data expected in the first half of 2026 ~ ~ Presented updated Phase I/II data from AMT-191 in Fabry disease showing durable, dose-dependent increases in α-Gal ...

March 2, 2026 1 EN
 PRESS RELEASE
Free
QURE UNIQURE NV

uniQure Provides Regulatory Update on AMT-130 for Huntington’s Disease

uniQure Provides Regulatory Update on AMT-130 for Huntington’s Disease LEXINGTON, Mass. and AMSTERDAM, March 02, 2026 (GLOBE NEWSWIRE) -- N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that the company received final meeting minutes from the U.S. Food and Drug Administration (FDA) regarding a Type A meeting held on January 30, 2026 to discuss AMT-130, an investigational gene therapy for Huntington’s disease (HD).   The FDA stated that it cannot agree that data from the Phase I/II studies, com...

March 2, 2026 1 EN
 PRESS RELEASE
Free
QURE UNIQURE NV

uniQure to Announce 2025 Financial Results

uniQure to Announce 2025 Financial Results ~ uniQure to host earnings call on Monday, March 2, 2026 at 8:00 a.m. ET ~ LEXINGTON, Mass. and AMSTERDAM, Feb. 23, 2026 (GLOBE NEWSWIRE) -- N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs will report fourth quarter and full year of 2025 financial results before market open on Monday, March 2, 2026. Management will then host a conference call at 8:00 a.m. ET. The event will be webcast under the Events & Presentations section of uniQure’s website at , and following t...

February 23, 2026 1 EN
 PRESS RELEASE
Free
QURE UNIQURE NV

uniQure Announces Updated Preliminary AMT-191 Phase I/IIa Data Showing...

uniQure Announces Updated Preliminary AMT-191 Phase I/IIa Data Showing Sustained Increases in α-Gal A Enzyme Activity in Patients with Fabry Disease ~ Supraphysiological expression of α-Gal A activity maintained for over a year in longest treated patient as of data cutoff date ~ ~ Stable Lyso-Gb3 levels maintained post-dosing, regardless of enzyme replacement therapy status across all cohorts ~ ~ Six of 11 patients have discontinued enzyme replacement therapy as of data cutoff date ~ LEXINGTON, Mass. and AMSTERDAM, Feb. 06, 2026 (GLOBE NEWSWIRE) -- N.V. (NASDAQ: QURE), a leading gene ...

February 6, 2026 1 EN
 PRESS RELEASE
Free
QURE UNIQURE NV

uniQure Announces Type A Meeting Scheduled with FDA

uniQure Announces Type A Meeting Scheduled with FDA LEXINGTON, Mass. and AMSTERDAM, Jan. 09, 2026 (GLOBE NEWSWIRE) -- N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced a Type A meeting with the U.S. Food and Drug Administration (FDA) has been scheduled to discuss the Biologics License Application (BLA) data package to support accelerated approval of AMT-130, the Company’s investigational gene therapy for the treatment of Huntington’s disease. “We look forward to a constructive discussion with th...

January 9, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch